Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
BAUSCH HEALTH (US), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date April 5, 2022, the closing price was USD 23.23 and its ...
BAUSCH HEALTH (CA), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date March 22, 2022, the closing price was CAD 30.24 and its...
Current market expectations for IIVI don't comprehend the company's macro tailwinds. The company supplies the technology that allows big macro trends around 5G, the Internet of Things, and autonomous vehicles to bloom. Its tailwinds from these markets continue to take off, and in the case of autonomous vehicles, it is essential to any success at all. As booming demand accelerates in these end markets, the company is likely to see strong fundamental momentum the market isn't pricing in, both...
Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.5x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about their debt issues, Solta and B&L spinoffs, and their revenue guidance, market expectations are overly bearish, and longer-term equity outperformance is warranted. Specifically, management may lack confidence in their ability to continue to pay d...
Even after the company's impressive rally, current market expectations for PENN are still too pessimistic. While markets expect UAFRS-based ROA (Uniform ROA or ROA') to improve to levels not seen since 2010-2012, the company has significant further upside in returns, and therefore valuations. The market is not fully recognizing how the company's sports betting strategy, centered around its Barstool investment, can help significantly turbocharge returns and also give a material lift to the exis...
Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 13.0x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, revenue and margin growth, and the potential of their treatment trials, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may lack confidence in their a...
LPLA has significantly transformed their business returns, but the market is expecting the company to give operational improvements back. The market is expecting UAFRS-based (Uniform) ROA (ROA') to fade from 30% in 2019 to 18% in 2024, with Uniform asset growth of around 7.5% a year going forward. The market does not think the company's improvement in Uniform ROA from 15%-20% levels historically to towards 30%+ is sustainable, and is expecting the company to see its operating leverage rever...
Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.3x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, their R&D pipeline, and new product launches, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may have concerns about the impact of potential divestit...
Current market expectations for CVS are excessively pessimistic. Markets expect UAFRS-based (Uniform) ROA (ROA') to roll over to prior lows from 2010-2011. However, the company's fundamental strategy is likely to lead to continued ROA' expansion. CVS has been evolving into a full-service healthcare firm since their acquisition of Caremark in 2007, which led to initial ROA' expansion to 15%-17% levels. This was followed by continued investment in healthcare solutions and monetizing their data o...
Bausch Health Companies Inc. (BHC:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with a 9.2x Uniform P/E, implying bearish expectations for the firm. However, although management appears concerned about the Bausch + Lomb spinoff, operational cash flow guidance, and inventory management, market expectations are overly bearish, and longer-term equity outperformance is warranted Specifically, management may lack confidence in their ability to meet t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.